提高透析液镁浓度对终末期肾病患者血清钙化倾向的影响:一项随机对照临床试验
本研究为单中心、随机、双盲、平行组对照试验,比较透析液镁浓度从1.0提升至2.0 mEq/L并持续28天与维持1.0 mEq/L对终末期肾病血液透析患者T50的影响。结果显示高镁组随访时T50较对照组高73分钟(95%CI 30-116,P<0.001),血清镁组间差0.88 mg/dl(95%CI 0.66-1.10,P=0.001),提示提高透析液镁可增加T50、降低钙化倾向。
要点
- 提高透析液镁浓度可显著延长T50,降低血清钙化倾向。
- 血清镁组间差0.88 mg/dl,与T50改善相关。
- T50较低与ESKD患者心血管事件和死亡风险较高相关。
核心结论
- 提高透析液镁浓度可增加T50,从而降低维持性血液透析患者的钙化倾向。
研究设计与样本
- 单中心、随机、双盲、平行组对照临床试验,比较透析液镁1.0与2.0 mEq/L干预28天。
- 主要终点为干预结束时T50值。
主要发现
- 标准镁组T50基线233±81分钟,随访229±93分钟;高镁组基线247±69分钟,随访302±66分钟。
- 随访时T50组间差73分钟(95%CI 30-116,P<0.001)。
- 血清镁组间差0.88 mg/dl(95%CI 0.66-1.10,P=0.001)。
临床怎么用
- 对于维持性血液透析的ESKD患者,可考虑提高透析液镁浓度以增加T50、降低钙化倾向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Serum calcification propensity is measured by T50, the time taken to convert from primary to secondary calciprotein particle in the serum. Lower T50 represents higher calcification propensity and is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases T50, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on T50 in subjects undergoing hemodialysis for ESKD. The primary end point was the value of T50 at the end of the intervention. RESULTS: Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, T50 was 233±81 minutes (mean±SD) at baseline (mean of days -7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, T50 was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in T50 between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116; P<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10; P=0.001). CONCLUSIONS: Increasing dialysate magnesium increases T50 and hence, decreases calcification propensity in subjects undergoing maintenance hemodialysis. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3.
引用
- Bressendorff I, Hansen D, Schou M, et al. The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol. 2018. PMID: 30131425. doi:10.2215/CJN.13921217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。